Argireline vs Matrixyl: Mechanisms, Trials and Which to Use

Direct answer: In Argireline vs Matrixyl, the peptides target different things. Argireline (acetyl hexapeptide-8) aims at expression lines by interfering with nerve-to-muscle signaling. Matrixyl (palmitoyl pentapeptide-4) is a collagen-signaling peptide aimed at fine lines. The only head-to-head trial, 21 women over 8 weeks, favored Matrixyl. Evidence: limited.

Key takeaways

• They do different jobs. In the lab, Argireline disrupts the protein machinery that releases neurotransmitters. Matrixyl acts as a matrikine, a small protein fragment that signals cells to make more matrix. Evidence: lab only, for both mechanisms.
• Matrixyl's best trial is bigger and longer. That trial was run by the company that made the product. Argireline's best trial lasted only 4 weeks. Evidence: limited, for both.
• One small trial compared them directly and favored Matrixyl. Its authors call it an "initial study." Evidence: early / preliminary.
• You can't compare their percentages. Matrixyl was tested at 3 parts per million (ppm). Argireline was tested at 10%.
• No trial has tested them together. A retinoid has far more evidence than either peptide.

What is the difference between Argireline and Matrixyl?

Argireline is a neurotransmitter-inhibiting peptide aimed at expression lines, while Matrixyl is a signal peptide aimed at collagen and fine lines. They work by different proposed mechanisms.

Peptides used in skincare are usually sorted into 4 groups: signal, carrier, neurotransmitter-inhibiting and enzyme-inhibiting (Gorouhi & Maibach, 2009). Argireline belongs to the neurotransmitter-inhibiting group and Matrixyl to the signal group. That difference explains most of what follows. For the full background, see our guide to peptide ingredients, and for Argireline specifically, read what Argireline does in skin.

Argireline came out of a rational-design program. Its sequence is Ac-EEMQRR-NH2. In vitro, it inhibited neurotransmitter release with a potency similar to botulinum toxin A but "much lower efficacy." It does this by interfering with the formation and stability of the SNARE complex, the protein bundle that lets nerve endings release their signal (Blanes-Mira et al., 2002). Evidence: lab only for the mechanism.

Matrixyl is pentapeptide-4 (KTTKS) attached to palmitic acid, a fatty acid. In cultured human dermal and corneal fibroblasts (the cells that make collagen), it increased collagen production in a concentration-dependent way. The effect appeared near the concentration at which the peptide starts to self-assemble (Jones et al., 2013). Evidence: lab only. More collagen in a dish does not mean more collagen in your skin.

Argireline vs Matrixyl: side-by-side comparison

Neither ingredient is listed with an anti-wrinkle or muscle-relaxing function in CosIng. That says nothing for or against efficacy. It does mean the official function is narrower than what the marketing claims.

Argireline vs Matrixyl: which has better human trials?

Matrixyl has the larger trial (93 women, 12 weeks, manufacturer-run), and the only head-to-head trial (21 women, 8 weeks) favored Matrixyl. Both evidence bases are limited.

Matrixyl: one larger trial, run by the manufacturer

Procter & Gamble researchers ran a 12-week, double-blind, placebo-controlled, split-face trial in 93 Caucasian women aged 35–55. One side of each face got a moisturizer with 3 ppm palmitoyl pentapeptide-4 and the other side got the same moisturizer without the peptide. Quantitative image analysis and expert graders both found significant improvement in wrinkles and fine lines versus placebo. Participants' self-assessments also improved, and the product was well tolerated (Robinson et al., 2005). Evidence: limited (single trial, run by the manufacturer, not independently replicated).

Argireline: a short independent trial

The best Argireline trial randomized 60 Chinese participants 3:1 to Argireline or placebo, applied around the eyes twice daily for 4 weeks. In the Argireline group, 48.9% were rated as responders on a subjective "total anti-wrinkle efficacy" scale, against 0% on placebo. Roughness measured on silicone skin replicas fell significantly with Argireline (p<0.01) but not with placebo (Wang et al., 2013). The 48.9% figure is a responder rating, not a 48.9% reduction in wrinkle depth. The concentration and funder are not reported in the abstract. The same trial was published in a second paper, so it counts as 1 trial, not 2 (Wang et al., 2013b). Evidence: limited.

The developer's original paper reported wrinkle depth reductions of "up to 30%" after 30 days of a 10% emulsion in healthy women. The abstract does not report the sample size or control details (Blanes-Mira et al., 2002).

The only head-to-head trial

A double-blind randomized trial put 21 Indonesian women aged 26–55 into 3 groups: acetyl hexapeptide-3 cream, palmitoyl pentapeptide-4 cream, or placebo. Each cream was applied twice daily to crow's feet for 8 weeks. The researchers measured hydration, water loss and elasticity and took standardized photos. Palmitoyl pentapeptide-4 did better than both Argireline and placebo. The authors reported no conflicts of interest and called it an "initial study" that needs more participants and a longer follow-up (Aruan et al., 2023). Concentrations are not reported in the abstract. Evidence: early / preliminary.

Can either one get where it needs to go?

Probably not far. Lab data show very little Argireline gets past the outer skin layer, and neither peptide has been shown to reach the dermis from a normal cream.

Whether either peptide reaches its target is Argireline's biggest open question. In an FDA in-vitro study, a 10% Argireline emulsion was applied to human cadaver skin for 24 hours. Most of it washed off the surface. Only 0.22% of the dose was found in the stratum corneum and 0.01% in the epidermis, and none was detected in the dermis (Kraeling et al., 2015). Other researchers describe its permeation as "poor" because of its size and water-loving, charged structure (Lim et al., 2018). A 2025 review says its ability to reach the neuromuscular junction "remains uncertain" (Zdrada-Nowak et al., 2025).

For Matrixyl, our sources don't include a human skin-penetration study of palmitoyl pentapeptide-4. Pal-KTTKS stayed stable in skin homogenate for up to 8 hours (Errante et al., 2021). That shows stability, not delivery. Most anti-wrinkle peptides are poor candidates for skin permeation in general (Mortazavi & Moghimi, 2022). Our article on whether peptides absorb into skin covers this in more depth.

Can you compare Argireline and Matrixyl percentages directly?

No. The two peptides are used at very different concentrations and measured with different endpoints, so a bigger number on the label doesn't mean a stronger product.

A Matrixyl serum might list a tiny amount and an Argireline serum might say "10%." That does not make the Argireline product stronger. The Matrixyl trial used 3 ppm, which is 0.0003% (Robinson et al., 2005). The 2024 Cosmetic Ingredient Review (CIR) safety report lists 0.0012% as the highest reported leave-on concentration, in eye lotions. That figure comes from 239 reported formulations, 223 of them leave-on (CIR, 2024). Argireline studies used 10% emulsions (Blanes-Mira et al., 2002; Kraeling et al., 2015).

These are different molecules with different targets and different effective concentrations. The only fair comparison is to check each product against the concentration that was tested for that peptide. If a label doesn't say whether its percentage means pure peptide or a supplier solution, ask the brand.

Is Matrixyl the same as Matrixyl 3000?

"Matrixyl" on its own usually means palmitoyl pentapeptide-4, which some papers still call palmitoyl pentapeptide-3 (Tałałaj et al., 2019). Matrixyl 3000 is a different ingredient: a blend of palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7. The 93-person Robinson trial and the head-to-head trial both tested palmitoyl pentapeptide-4, so their results don't carry over to Matrixyl 3000.

In a 2026 study, Matrixyl 3000 peptides were detected throughout the stratum corneum, between the cells, in 3 volunteers. The co-authors were from Boots/No7 (Trzaska et al., 2026). Evidence: early / preliminary. Check the INCI list on your product to see which one you actually have.

Can you use Argireline and Matrixyl together?

Yes, as far as anyone knows. No trial has tested the combination, but nothing suggests they interfere with each other.

Stacking the two is a common pattern in skincare communities, often with Matrixyl 3000 rather than palmitoyl pentapeptide-4. No trial has tested Argireline and Matrixyl in combination. The nearest data is a 60-day, 4-arm trial in 24 volunteers (about 6 per arm). It paired acetyl hexapeptide-3 with tripeptide-10 citrulline, which is not Matrixyl. The pairwise differences were mixed, and the mechanism of any synergy was unclear (Raikou et al., 2017). Evidence: early / preliminary.

Practical guidance (our suggestion, not trial-tested):

• Use Argireline in a water-rich product. In porcine skin, a water-in-oil-in-water emulsion delivered significantly more acetyl hexapeptide-8 than oil-in-water or water-in-oil versions, and water-rich formulas did better than oil-rich ones (Hoppel et al., 2015).
• A common routine order is the thinner, water-based serum first and the creamier peptide product after. No study has compared application orders.
• Add one product at a time, about 2 weeks apart, so you can tell which one causes any change you notice.

Forehead or under-eye?

People often ask which peptide to use for forehead lines and which for under-eye lines. The placebo-controlled Argireline trial and the head-to-head trial both tested the area around the eyes (Wang et al., 2013; Aruan et al., 2023). The abstracts we reviewed include no forehead-specific trial of either peptide.

Some users report that forehead lines or under-eye lines looked deeper within a few days to about 2 weeks of starting Argireline. In some of these reports, the lines went back to baseline after stopping. No study explains this pattern. Possible confounders include changes in hydration, a water-based serum drying down on the skin, and differences in lighting or expression between photos. If you notice it, stop and see whether your skin returns to baseline. Our Argireline before-and-after article explains how to take photos you can compare fairly.

Is a subtle change normal after 2 months?

Yes. Subtle results match what the trials measured. The trials lasted 4 weeks (Argireline), 8 weeks (head-to-head) and 12 weeks (Matrixyl). They relied on image analysis, skin replicas and grader scores, and none described dramatic visible change (Wang et al., 2013; Aruan et al., 2023; Robinson et al., 2005). For comparison, the retinol trial below ran for 24 weeks. If you see nothing at 12 weeks with Matrixyl, the evidence gives you little reason to expect more from continuing.

Can you combine Argireline or Matrixyl with copper peptides or retinol?

We found no interaction data for Argireline or Matrixyl combined with copper peptides. For a direct comparison of those two signal peptides, see Matrixyl vs copper peptides and our overview of copper peptides for skin.

Retinoids have a much deeper evidence base (Mukherjee et al., 2006). In one example, 36 older adults used 0.4% retinol or vehicle for 24 weeks. Fine wrinkle scores changed by −1.64 with retinol versus −0.08 with vehicle (Kafi et al., 2007). Evidence: well-established for retinoids overall. The CIR report also mentions an 8-week study in 196 women. It compared a multi-ingredient regimen, which included palmitoyl pentapeptide-4, niacinamide and retinyl propionate, against prescription 0.02% tretinoin. The peptide concentration was not provided, so the result can't be credited to Matrixyl (CIR, 2024). We have a separate article on peptides and retinol in progress.

Are Argireline and Matrixyl safe?

Both appear low-irritation in the published studies, though safety data are limited to small trials and manufacturer testing.

The Argireline developer reported no oral toxicity or primary irritation at high doses (Blanes-Mira et al., 2002). In a 2004 radiotherapy trial (n=20), a cream containing Matrixyl and other ingredients caused mild itchiness more often than the comparison lotion, and 1 suspected allergic reaction was recorded (Röper et al., 2004). Argireline is a topical ingredient. One case report describes a serious mycobacterial skin infection after Argireline was injected into the forehead and temples (Chen et al., 2021).

About the brochure numbers

You may see "68% less wrinkle density / 45% less depth" quoted for Matrixyl and "17% / 27%" for Argireline. These figures come from supplier marketing material (Sederma and Lipotec). We found no peer-reviewed source for any of them, so treat them as unverified claims.

Where the evidence stops

• No independent replication of the 93-person Matrixyl trial.
• No Argireline trial longer than 4 weeks with placebo results published. A 70-person periorbital trial registered by Mahidol University was completed in 2009 but has posted no results (NCT01381484).
• The only head-to-head trial had 21 people. Its abstract doesn't report concentrations.
• No combination trial of Argireline with Matrixyl, copper peptides or retinoids.
• Penetration is unresolved for Argireline and unstudied in humans for palmitoyl pentapeptide-4.
• We don't know yet whether either peptide changes collagen in human skin.

FAQ

Is Argireline or Matrixyl better for crow's feet? The only head-to-head trial found palmitoyl pentapeptide-4 did better than Argireline and placebo over 8 weeks (Aruan et al., 2023). It had only 21 participants, so treat the result as preliminary.

Can I use Argireline and Matrixyl together? No trial has tested the combination, so there are no efficacy or interaction data. Many people stack them anyway. If you do, add them one at a time so you can spot any reaction.

Is it normal to see only subtle results after 2 months? Yes. The trials measured modest changes with instruments and graders over 4–12 weeks (Robinson et al., 2005; Wang et al., 2013).

Can Argireline make forehead lines look worse? Some users report lines looking deeper within the first 2 weeks. No study has examined this. Hydration changes and photo conditions could explain some of these reports, but that hasn't been tested.

Is Matrixyl the same as Matrixyl 3000? No. Matrixyl is palmitoyl pentapeptide-4. Matrixyl 3000 combines palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7, and its human evidence is separate and smaller (Trzaska et al., 2026).

Can I use these peptides with retinol or copper peptides? There are no interaction studies for either combination. Retinol has stronger anti-wrinkle evidence than either peptide (Kafi et al., 2007). Ask a dermatologist about prescription retinoids.

References

Full titles are available on each linked record.

1. Blanes-Mira C, et al. Int J Cosmet Sci. 2002. Developer study; in vitro plus 30-day emulsion test, n not reported in the abstract. https://pubmed.ncbi.nlm.nih.gov/18498523/
2. Wang Y, et al. Am J Clin Dermatol. 2013. Placebo-controlled RCT, n=60, 4 weeks. https://pubmed.ncbi.nlm.nih.gov/23417317/
3. Wang Y, et al. J Cosmet Laser Ther. 2013. Second report of the same 60-person trial plus a mouse arm. https://pubmed.ncbi.nlm.nih.gov/23607739/
4. Aruan RR, et al. J Clin Aesthet Dermatol. 2023. Double-blind 3-arm RCT, n=21, 8 weeks. https://pubmed.ncbi.nlm.nih.gov/36909866/
5. Robinson LR, et al. Int J Cosmet Sci. 2005. Split-face placebo-controlled RCT, n=93, 12 weeks; Procter & Gamble authors. https://pubmed.ncbi.nlm.nih.gov/18492182/
6. Jones RR, et al. Mol Pharm. 2013. In vitro, human fibroblasts. https://pubmed.ncbi.nlm.nih.gov/23320752/
7. Kraeling ME, et al. Cutan Ocul Toxicol. 2015. In vitro diffusion study, human and guinea pig skin. https://pubmed.ncbi.nlm.nih.gov/24754410/
8. Hoppel M, et al. Eur J Pharm Sci. 2015. In vitro, porcine skin. https://pubmed.ncbi.nlm.nih.gov/25497319/
9. Lim SH, et al. Sci Rep. 2018. In vitro permeation, peptide analogues. https://pubmed.ncbi.nlm.nih.gov/29371611/
10. Zdrada-Nowak J, et al. Int J Mol Sci. 2025. Review. https://pubmed.ncbi.nlm.nih.gov/40565185/
11. Mortazavi, Moghimi. Int J Cosmet Sci. 2022. Review. https://pubmed.ncbi.nlm.nih.gov/35302659/
12. Errante, et al. 2021. Stability in skin homogenate. https://pubmed.ncbi.nlm.nih.gov/33281001/
13. Trzaska, et al. 2026. Matrixyl 3000 penetration, n=3. https://pubmed.ncbi.nlm.nih.gov/42790608/
14. Tałałaj, et al. Molecules. 2019. Review (nomenclature). https://pubmed.ncbi.nlm.nih.gov/31618846/
15. Raikou V, et al. J Cosmet Dermatol. 2017. 4-arm RCT, n=24, 60 days. https://pubmed.ncbi.nlm.nih.gov/28150423/
16. Gorouhi F, Maibach HI. 2009. Review (peptide classes). https://pubmed.ncbi.nlm.nih.gov/19570099/
17. Kafi R, et al. 2007. Vehicle-controlled RCT, n=36, 24 weeks. https://pubmed.ncbi.nlm.nih.gov/17515510/
18. Mukherjee S, et al. 2006. Review (retinoids). https://pubmed.ncbi.nlm.nih.gov/18046911/
19. Röper B, et al. Strahlenther Onkol. 2004. RCT, n=20, radiotherapy patients. https://pubmed.ncbi.nlm.nih.gov/15127162/

Also cited: Cosmetic Ingredient Review, Final Report on Pentapeptides, September 2024 (https://www.cir-safety.org/sites/default/files/FR_Pentapeptides_092024.pdf); European Commission CosIng database, accessed October 10, 2026 (https://ec.europa.eu/growth/tools-databases/cosing/); Chen CF, et al. World J Clin Cases. 2021. Case report. https://pubmed.ncbi.nlm.nih.gov/33748252/; ClinicalTrials.gov NCT01381484.

Disclosure: This article contains no affiliate links. It is for educational purposes only and is not medical advice. Talk to a dermatologist or other qualified clinician before starting prescription treatments or if you have a skin condition.

For educational purposes only; not medical advice. See our disclaimer and research method.